Sector Watch: Healthcare - Mar 22 2019
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $108.17 -3.80 -3.39% | XBI: $87.86 -4.06 -4.42% | Updated Mar 22, 2019 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| SNSS Sunesis Pharmaceuticals $84.5M |
1.25+0.29 3.7 M 6.4x |
30% | ||
| BPTH Bio-Path Holdings $55.1M |
21.98+3.50 4.1 M |
19% | ||
| IMMP Immutep $118.4M |
2.57+0.33 11.5 M 178.6x |
15% | ||
| SRNE Sorrento Therapeutics $726.3M |
5.94+0.71 29.5 M 10.9x |
14% | ||
| CPIX Cumberland Pharmaceuticals $100.4M |
6.50+0.60 5.0 K |
10% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| LXRX52WL Lexicon Pharmaceuticals $658.9M |
6.20-1.74 3.3 M 3.4x |
-22% | ||
| TRIB Trinity Biotech $57.7M |
2.40-0.54 100.9 K 3.0x |
-18% | ||
| NVAX Novavax $238.8M |
0.54-0.08 24.8 M |
-13% | ||
| CNCE Concert Pharmaceuticals $364.9M |
15.51-2.03 148.5 K |
-12% | ||
| VKTX Viking Therapeutics $594.6M |
8.26-1.02 3.6 M |
-11% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
FDA Issues Complete Response Letter for Zynquista? (sotagliflozin) [globenewswire.com]Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes [globenewswire.com]
Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin) [globenewswire.com]
Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management [globenewswire.com]
Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer [globenewswire.com]
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact the Firm [globenewswire.com]
Bio-Path Holdings Reports Full Year 2018 Financial Results [globenewswire.com]
Immutep to Present IMP761 Preclinical Results in Global Webcast [globenewswire.com]
Novavax Reports Fourth Quarter and Year-End 2018 Financial Results [globenewswire.com]
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019 [globenewswire.com]
(LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019 [globenewswire.com]
Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer Nasdaq:LXRX [globenewswire.com]
Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update [globenewswire.com]
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides a Business Update [globenewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
